Christopher L. Corless

Archive Network Publication Hotspot Collaboration

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Christopher L. Corless is active.

Explore More

Publication

Featured researches published by Christopher L. Corless.

Journal of Clinical Oncology | 2010

Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001.

Christopher L. Corless; Karla V. Ballman; Cristina R. Antonescu; Charles D. Blanke; Martin E. Blackstein; George D. Demetri; M. von Mehren; R. Maki; Peter W.T. Pisters; Ronald P. DeMatteo

Journal of Clinical Oncology | 2011

A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU).

S. George; M. von Mehren; Michael C. Heinrich; Qian Wang; Christopher L. Corless; James E. Butrynski; Jeffrey A. Morgan; Andrew J. Wagner; Edwin Choy; William D. Tap; Judith Manola; Jeffrey T. Yap; A. D. Van Den Abbeele; Scott D. Solomon; Jonathan A. Fletcher; George D. Demetri

Journal of Clinical Oncology | 2006

Long-term follow-up of a phase II randomized trial in advanced gastrointestinal stromal tumor (GIST) patients (pts) treated with imatinib mesylate

Charles D. Blanke; George D. Demetri; M. von Mehren; Michael C. Heinrich; Burton L. Eisenberg; Jonathan A. Fletcher; Christopher L. Corless; E. Wehrle; K. B. Sandau; Heikki Joensuu

Journal of Clinical Oncology | 2006

Sunitinib treatment of pediatric metastatic GIST after failure of imatinib

Katherine A. Janeway; D. C. Matthews; James E. Butrynski; Gina D'Amato; S. Agresta; Chris R. Garrett; Christopher L. Corless; Karen Albritton; George D. Demetri

Journal of Clinical Oncology | 2008

Insulin-like growth factor 1 receptor (IGF-1R): A potential therapeutic target for gastrointestinal stromal tumors (GIST)

Andrew K. Godwin; Lori Rink; T. Chi; Douglas B. Flieder; Joseph R. Testa; Christopher L. Corless; Michael C. Heinrich; Burton L. Eisenberg; M. von Mehren

Journal of Clinical Oncology | 2016

Evaluation of the presence of IGF1R overexpression in wild-type and kinase mutant GI stromal tumors

Christopher L. Corless; Carol Beadling; E. Justusson; Michael C. Heinrich

Journal of Clinical Oncology | 2010

Mass spectroscopy-based cancer genotyping of 800 patients enrolled in a personalized cancer medicine registry.

Carol Beadling; Michael C. Heinrich; Kathryn G. Schuff; Brian J. Druker; Christopher L. Corless

Archive | 2003

KIT as a Therapeutic Target

Michael C. Heinrich; Charles D. Blanke; Christopher L. Corless; Brian J. Druker

Journal of Clinical Oncology | 2010

Coexistence of gastrointestinal stromal tumor (GIST) with desmoid tumor (DT): Case series of 22 patients.

A. G. Dumont; Lori Rink; Markku Miettinen; Heikki Joensuu; Jonathan R. Strosberg; Alessandro Gronchi; Christopher L. Corless; Alexander J. Lazar; Dina Lev; M. von Mehren

Ejc Supplements | 2007

7506 ORAL Up to 6 years follow-up of patients receiving imatinib mesylate (Glivec) to treat unresectable or metastatic gastrointestinal stromal tumors (GISTs)

Heikki Joensuu; George D. Demetri; Michael C. Heinrich; Burton L. Eisenberg; Jonathan A. Fletcher; Christopher L. Corless; Christopher D. M. Fletcher; Charles D. Blanke; D. Heintz; M. von Mehren

Explore More